Is Your Paper Ready for European Heart Journal? The ESC's Flagship Standard

This is the single most important fact about EHJ that most submitting authors don't know. Editors reject approximately 90% of single-center observational studies at the desk. Not after review. Before a single external reviewer sees the paper.

The reasoning isn't arbitrary. Single-center studies carry inherent limitations in generalizability, and EHJ's editors have decided that those limitations almost always outweigh the findings. When your data comes from one hospital, one patient population, one set of clinical protocols, the editors can't be confident that the results apply across the diverse healthcare systems that ESC guidelines cover. A finding from a tertiary referral center in Munich may not translate to community hospitals in Portugal or rural clinics in Poland.

There are three exceptions, and they're narrow:

Novel surgical techniques. If your center has developed a new surgical approach that can only be evaluated where it was pioneered, a single-center study is the only option. The editors understand this. But the technique needs to be genuinely new, not an incremental modification of an established procedure.

Rare disease series. Some conditions are so uncommon that only a handful of centers worldwide have enough patients to study them. A single-center series on cardiac sarcoidosis with unusual presentations, or a rare congenital heart defect with limited surgical options, can clear the bar because multicenter data simply doesn't exist.

Methodological innovations. If your paper introduces a new imaging protocol, a novel biomarker assay, or a computational method that happens to be validated at one center, the single-center limitation is acceptable. The contribution is the method, not the population-level finding.

Everything else? If you're sitting on a single-center observational cohort study showing that Biomarker X predicts outcomes in patients with heart failure, and your sample size is 300-500 patients from one hospital, don't submit to EHJ. The desk rejection will arrive quickly, and you'll have lost time you could have spent formatting for a journal that's more receptive to that study design.

EHJ enforces formatting standards with unusual strictness. At many top journals, formatting issues result in a polite request to revise and resubmit. At EHJ, formatting noncompliance can trigger a desk rejection before the science is evaluated at all.

This isn't a minor concern. Oxford University Press, which handles EHJ's production, has established specific technical requirements that manuscripts must meet before they enter the editorial workflow. Papers that arrive with incorrect reference formatting, figures that don't meet resolution standards, or word counts that exceed limits get flagged before an editor ever looks at the abstract.

The practical implication: read the author guidelines completely, not the summary version. EHJ's instructions for authors are detailed, and they mean what they say. Word limits are word limits, not suggestions. Figure specifications are checked, not eyeballed. Reference formatting follows the journal's house style exactly.

A few formatting traps that catch researchers who are used to more forgiving journals:

• Structured abstract requirements. EHJ requires structured abstracts with specific headings. Submitting an unstructured abstract, even if it contains the same information, signals that you didn't read the guidelines.
• Figure and table formatting. Resolution requirements, font sizes within figures, and color specifications are enforced. A figure that looks fine on your screen may not meet production standards.
• Word count enforcement. EHJ has strict word limits for different article types. Going 200 words over isn't going to be forgiven the way it might be at other journals.
• Cover letter content. The cover letter should explain why EHJ is the right venue, including how the work relates to ESC guidelines or European clinical practice.

The lesson: format your manuscript to EHJ's exact specifications before you submit. Don't assume that strong science will override sloppy formatting. The editors interpret formatting noncompliance as a signal that the authors didn't take the submission seriously.

EHJ and Circulation are frequently compared, and researchers often submit to both sequentially. But they aren't interchangeable, and understanding the differences can save you months of misdirected effort.

The numbers are close enough that impact factor shouldn't drive your decision. What should drive it is editorial philosophy and geographic alignment.

Circulation thinks in terms of AHA/ACC guidelines. If your clinical trial could change an American Heart Association practice guideline, Circulation is the natural home. The editors evaluate clinical relevance through the lens of US cardiology practice, US patient populations, and US treatment standards.

EHJ thinks in terms of ESC guidelines. If your trial tested an intervention recommended by ESC guidelines, used European patient populations, or addresses a clinical question with particular relevance to European healthcare systems, EHJ is where it belongs. A European multicenter trial comparing therapies against ESC-recommended standards will resonate more strongly with EHJ's editors than with Circulation's.

There's also a philosophical difference that goes beyond geography. Circulation demands an immediate clinical takeaway. Their required "What Is New?" and "What Are the Clinical Implications?" boxes force you to articulate exactly what a practicing cardiologist should do differently. EHJ is somewhat more receptive to studies that advance mechanistic understanding of cardiovascular disease, imaging innovations, or translational findings that connect pathophysiology to clinical phenotypes, even when the direct practice implications are a step removed.

That doesn't mean EHJ publishes basic science. It doesn't. But the editorial bar for "how directly does this change what a clinician does tomorrow" is slightly more flexible at EHJ than at Circulation, where clinical immediacy is non-negotiable.

The society affiliation factor. This is something researchers underestimate. If your co-authors sit on ESC guideline committees, if your trial was endorsed by an ESC working group, or if your research program has institutional connections to the ESC, there's an alignment advantage at EHJ. The same applies in reverse for AHA-affiliated researchers and Circulation. This isn't bias. It's editorial coherence. The editors are looking for papers that fit their society's mission and clinical priorities.

EHJ doesn't just publish alongside ESC guidelines. It publishes the guidelines themselves. Every major ESC clinical practice guideline appears in EHJ, and those guidelines drive the journal's editorial priorities in ways that affect every original research submission.

When EHJ editors triage your manuscript, they're implicitly asking: does this paper speak to an active guideline question? The ESC updates its clinical practice guidelines on a rolling basis, and the topics under active revision represent the editorial sweet spots. If the ESC is currently updating its guidelines on chronic heart failure, a large trial testing a new heart failure therapy has inherently higher editorial interest than it would in an off-cycle year.

This means you should know which ESC guidelines are currently under revision before you submit. Check the ESC website for their guideline timeline. If your research directly addresses a question that a guideline committee is actively debating, mention it in your cover letter. Not as a sales pitch, but as context. "This trial provides evidence relevant to the ongoing ESC guideline revision on [topic]" tells the editor exactly why your paper matters right now.

Conversely, if your paper addresses a topic where the ESC guidelines were just updated and the evidence base is considered settled, the bar is higher. You'll need to show that your findings challenge the current recommendation, not just confirm it. Confirmatory evidence for existing guidelines rarely gets published in EHJ unless the study is massive or the clinical question has lingering controversy.

EHJ uses a single-anonymized peer review model. You know who the editors are. The reviewers know who you are. But you don't know who the reviewers are. This is the same model used by most top medical journals, and it has practical implications for how you write your manuscript.

Because reviewers can see your author list and institutional affiliations, there's no point in hiding who you are or where you work. But it also means that reviewers may come in with expectations based on your institution's reputation or your previous publications. A submission from a group known for cardiovascular imaging will be evaluated against that group's track record, for better or worse.

Here's the review workflow:

Fast initial triage. EHJ moves quickly on papers that don't meet editorial criteria. If your manuscript is going to be desk-rejected, you'll know relatively fast. The editors aren't sitting on borderline papers for weeks. They're making decisions.

At least two peer reviewers. Papers that pass triage are sent to a minimum of two external reviewers. These are working researchers and clinicians in cardiovascular medicine, selected by the handling editor based on expertise. The single-anonymized model means reviewers can look up your previous work, which can work in your favor if your group has a strong track record in the area.

Editor-mediated decision. After reviews come back, the handling editor synthesizes the reviewer comments and makes a recommendation. The final decision involves the editor-in-chief or a deputy editor. This isn't a simple majority vote on reviewer opinions. The editors weigh reviewer expertise, the quality of the arguments, and the paper's fit with EHJ's editorial priorities.

Before investing the time to format for EHJ's strict requirements, work through these questions:

1. Is your study multicenter? If it's single-center and observational, EHJ will almost certainly desk-reject it. The exceptions are narrow: novel surgical techniques, rare disease series, or methodological innovations.

1. Does your paper relate to an active ESC guideline question? Papers that inform ongoing guideline debates have a natural editorial advantage. Check which guidelines are currently under revision.

1. Is your study population European, or does it include European centers? EHJ publishes international research, but studies with European patient populations resonate more strongly with the editorial team.

1. Are your endpoints hard clinical outcomes? Mortality, MACE, hospitalization. Surrogate endpoints need strong justification and large sample sizes to compensate.

1. Have you met every formatting requirement? Read the full author guidelines, not a summary. Formatting noncompliance can get you desk-rejected before the science is evaluated.

1. Could this paper change an ESC practice recommendation? Not theoretically, not eventually. Within the current guideline cycle, could the ESC cite this paper?

1. Have you looked at recent EHJ publications in your area? Read five papers from the last year in your subspecialty. Are you operating at the same level of study design, sample size, and clinical impact?

1. Have you run your manuscript through a pre-submission check? A free manuscript assessment can flag scope misalignment, formatting issues, and structural problems that trigger desk rejection at EHJ. Catching these before submission saves weeks.

These aren't generic rejection reasons. They're patterns that specifically get papers rejected from European Heart Journal.

The single-center registry study. You've analyzed five years of data from your hospital's catheterization lab. Your sample is 800 patients, your outcomes are solid, and you've found an interesting risk factor. EHJ won't publish it. The 90% desk rejection rate for single-center observational studies applies here. Even if the statistics are perfect, the editors don't believe single-center data can support practice recommendations across European healthcare systems.

The US-only trial submitted without European framing. Your multicenter trial was conducted across 15 US hospitals, using AHA/ACC-recommended comparators. The science is strong. But EHJ's editors are asking: does this apply to European patients? Were the treatment standards comparable to what ESC guidelines recommend? If your paper reads as if it was written for Circulation, it'll feel out of place at EHJ. At minimum, your Discussion needs to address how the findings translate to European clinical practice.

The confirmatory study for settled guidelines. You've shown, in a large cohort, that an ESC-recommended therapy works as expected. That's not a paper for EHJ. The editors already knew the therapy works. That's why it's in the guidelines. Unless your study challenges the guideline, identifies an important exception, or discovers a significant subgroup effect, confirmatory evidence doesn't clear the bar.

The poorly formatted submission. This shouldn't be a failure mode, but it is. Researchers who are used to journals that accept imperfect formatting and fix it in production get tripped up by EHJ's pre-review formatting check. Your manuscript needs to be publication-ready in terms of formatting before it enters editorial triage. A brilliant study in the wrong reference format is still getting flagged.

The imaging study without clinical endpoints. You've validated a new cardiac MRI technique that detects myocardial fibrosis with greater sensitivity than existing methods. Technically impressive. But EHJ wants to know: does detecting fibrosis with greater sensitivity change patient outcomes? If your paper shows diagnostic accuracy without showing that better detection leads to different clinical decisions, the editors will direct you to a subspecialty imaging journal.

The genetic association study without therapeutic relevance. You've identified a variant associated with atrial fibrillation risk. Interesting. But EHJ wants the clinical utility. Does this variant identify patients who need earlier screening? Does it predict response to anticoagulation? Pure association data without therapeutic implications doesn't clear the editorial bar.

EHJ's editorial process moves at a pace that reflects its high submission volume and the editorial team's decisive triage approach.

• Desk rejection decision: Fast. Papers that don't meet editorial criteria are returned quickly, often within 1-2 weeks.
• Review assignment: Papers that pass triage are assigned to at least two reviewers, typically within a week of clearing the desk.
• First decision: Expect 3-5 weeks from submission to first decision for papers that go to review. This varies by reviewer availability and topic.
• Revision window: Major revisions typically get 60-90 days. Minor revisions get 30-45 days.
• Final decision after revision: Usually within 2-3 weeks of resubmission.
• Online publication: Accepted papers are published online within 1-2 weeks of final acceptance via Oxford University Press's Advance Access system.

The fast desk rejection process is actually a feature, not a bug. If your paper isn't going to make it, you'll know quickly and can redirect to another journal without losing months.

Don't submit to EHJ if:

Your study is single-center and observational. Unless it falls into one of the three narrow exceptions (novel surgical technique, rare disease, methodological innovation), submit elsewhere. JACC, Heart, or European Journal of Heart Failure may be better targets depending on your subspecialty.

Your findings are primarily relevant to US clinical practice. If your study tests AHA/ACC-recommended therapies, uses US patient populations, and addresses US treatment patterns, Circulation is the natural home.

Your paper is subspecialty-focused with limited crossover. A paper about cardiac resynchronization therapy outcomes in a specific device population might fit better in Europace (the ESC's electrophysiology journal) or European Journal of Heart Failure. EHJ wants findings that matter across cardiovascular medicine, not just within one subspecialty.

Your manuscript is basic science. EHJ doesn't publish preclinical research without clinical validation. Cardiovascular Research, also published by the ESC, is the society's basic science journal and a more appropriate target for mechanistic studies.

Formatting for EHJ takes real effort, and the strict pre-review checks mean that sloppy formatting won't be forgiven. Don't invest that time until you're confident the paper fits.

Read five recent EHJ original research articles in your area. Not just the abstracts. The full papers. Look at the study designs, the sample sizes, the endpoint selection, and the way the Discussion connects findings to ESC guidelines. Ask yourself whether your study operates at that level.

If it does, format carefully, write a cover letter that explains the ESC guideline relevance, and make sure every technical specification in the author guidelines is met before you click submit. EHJ's editors make fast decisions, and they're looking for papers where both the science and the formatting signal that the authors understand what this journal is.

If you're unsure about fit, run your manuscript through a pre-submission review before committing to EHJ's formatting requirements. Identifying scope misalignment or formatting gaps early prevents weeks of wasted effort and lets you redirect to a better-matched journal while the research is still timely.

1. How to choose the right journal for your paper, Manusights.